Tesevatinib
- Generic Name
- Tesevatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25Cl2FN4O2
- CAS Number
- 781613-23-8
- Unique Ingredient Identifier
- F6XM2TN5A1
- Background
Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.
Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.
- Associated Conditions
- -
- Associated Therapies
- -
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
- Conditions
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Kadmon, a Sanofi Company
- Target Recruit Count
- 80
- Registration Number
- NCT03203642
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸California Institute for Renal Research, La Mesa, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT03096080
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT02844439
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Center for Neurosciences, Tucson, Arizona, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
- Conditions
- Interventions
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT02616393
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸USC Norris Oncology/Hematology Newport Beach, Newport Beach, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
- Conditions
- Interventions
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT02616055
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT02154529
- Locations
- 🇺🇸
Laura and Isaac Perlmutter Cancer Center @ NYU Langone, New York, New York, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸San Juan Oncology, Farmington, New Mexico, United States
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Kadmon, a Sanofi Company
- Target Recruit Count
- 69
- Registration Number
- NCT01559363
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Colorado Denver, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.